Article
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
British journal of haematology - 1 Jul 2022
Voso Maria-Teresa, Pandzic Tatjana, Falconi Giulia, Denčić-Fekete Marija, De Bellis Eleonora, Scarfo Lydia, Ljungström Viktor, Iskas Michail, Del Poeta Giovanni, Ranghetti Pamela, Laidou Stamatia, Cristiano Antonio, Plevova Karla, Imbergamo Silvia, Engvall Marie, Zucchetto Antonella, Salvetti Chiara, Mauro Francesca R, Stavroyianni Niki, Cavelier Lucia, Ghia Paolo, Stamatopoulos Kostas, Fabiani Emiliano, Baliakas Panagiotis
Abstract excerpt
Clonal haematopoiesis of indeterminate potential (CHIP) may predispose for the development of therapy-related myeloid neoplasms (t-MN). Using target next-generation sequencing (t-NGS) panels and digital droplet polymerase chain reactions (ddPCR), we studied the myeloid gene mutation profiles of patients with chronic lymphocytic leukaemia (CLL) who developed a t-MN after treatment with chemo-(immuno)therapy. Using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.